Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-ESIDRIX #1 vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.
250 mg orally twice daily
Reserpine: 50-100 hours (terminal); clinical effects persist due to irreversible adrenergic neuron blockade. Hydrochlorothiazide: 6-15 hours (terminal).
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Reserpine: extensive hepatic metabolism; Hydrochlorothiazide: not significantly metabolized, excreted unchanged in urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Reserpine: renal (30% as metabolites, <1% unchanged), fecal (60% as metabolites). Hydrochlorothiazide: renal (>95% unchanged).
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Reserpine: 96% bound to albumin. Hydrochlorothiazide: 68% bound to plasma proteins.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Reserpine: 6-8 L/kg (extensive tissue binding, especially adrenergic neurons). Hydrochlorothiazide: 0.8-1.0 L/kg (enters erythrocytes).
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Reserpine: oral 30-50% (presystemic metabolism). Hydrochlorothiazide: oral 65-75%.
70-90% (oral); 100% (IV).
e GFR 30-50 m L/min: reduce dose by 50% or extend interval. e GFR <30 m L/min: contraindicated due to thiazide ineffectiveness.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: standard dosing. Child-Pugh B: reduce reserpine dose by 50%. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Reserpine: 0.005-0.02 mg/kg/day orally in 1-2 divided doses. Hydrochlorothiazide: 1-2 mg/kg/day orally in 2 divided doses. Adjust per response.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at half the standard dose (0.5 tablet orally daily). Titrate slowly due to increased sensitivity to hypotension, CNS depression, and electrolyte disturbances.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause mental depression, including suicidal risk,Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia),Orthostatic hypotension,Increased risk of arrhythmias with digoxin,May exacerbate systemic lupus erythematosus,May activate peptic ulcer,Monitor renal function and electrolytes
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
History of mental depression or suicidal thoughts,Active peptic ulcer,Ulcerative colitis,Electroconvulsive therapy (ECT) within 2 weeks,Anuria,Hypersensitivity to reserpine, hydrochlorothiazide, or sulfonamides
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-potassium foods (bananas, oranges, leafy greens) if taking potassium-sparing agents, but this combination does not include them. Limit sodium intake to enhance antihypertensive effect. Avoid grapefruit juice as it may increase reserpine absorption. Maintain adequate fluid intake but avoid excessive water intake due to risk of hyponatremia.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: Reserpine crosses placenta; associated with increased risk of congenital malformations (neural tube defects, cardiovascular anomalies) based on animal data and limited human reports. Second/third trimester: Use associated with fetal bradycardia, hypotonia, hypothermia, respiratory depression, and meconium ileus due to catecholamine depletion; risk of neonatal hypotension and poor feeding. Avoid in pregnancy unless benefit outweighs risk.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Reserpine excreted in breast milk; M/P ratio not established. Concentrations may be low but can cause infant respiratory depression, nasal congestion, and cyanosis. Hydrochlorothiazide also excreted; may suppress lactation. Contraindicated during breastfeeding.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No established safe dose; if unavoidable, use lowest effective dose. Pregnancy-induced hemodilution and increased renal clearance may reduce drug levels; however, due to toxicity, dose adjustment not recommended. Consider alternative antihypertensives (e.g., labetalol, nifedipine).
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Serpasil-Esidrix #1 combines reserpine (a Rauwolfia alkaloid) and hydrochlorothiazide (a thiazide diuretic). Reserpine depletes catecholamines and serotonin, causing gradual BP reduction. Onset of antihypertensive effect is delayed (2-3 weeks). Monitor for depression, nasal congestion, and extrapyramidal effects. Hydrochlorothiazide may cause hypokalemia, hyponatremia, and hyperglycemia. Avoid use in patients with history of depression, peptic ulcer, or electrolyte imbalances. Combination product offers convenience but fixed dosing limits titration.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not stop abruptly; sudden withdrawal may cause rapid blood pressure rise.,Report symptoms of depression, mood changes, or unusual tiredness promptly.,Avoid alcohol, which may increase dizziness and drowsiness.,Use sun protection; this drug increases photosensitivity risk.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,Weigh yourself regularly and report rapid weight gain or swelling.,Avoid potassium supplements or salt substitutes unless directed by your doctor.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-ESIDRIX #1 vs ALDOCLOR-250, answered by our medical review team.
SERPASIL-ESIDRIX #1 is a Antihypertensive Combination that works by Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-ESIDRIX #1 and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-ESIDRIX #1 is: 1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-ESIDRIX #1 and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-ESIDRIX #1 is classified as Category C. First trimester: Reserpine crosses placenta; associated with increased risk of congenital malformations (neural tube defects, cardiovascular anomalies) based on animal data and lim. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.